DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Motzer RJ, Rini BI, McDermott DF. et al.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol 2019;
20: 1370-1385
DOI: 10.1016/s1470-2045(19)30413-9.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.